20 Mar
Innovative Cancer Therapy for Tomorrow: Azacytidine plus Thalidomide in Myelodysplastic Syndromes and Acute Myelogenous Leukemia
Presenter: Azra Raza, MD, Professor of Medicine, and Chief of Hematology Oncology University of Massachusetts, Worcester, Massachusetts The DNA methyltransferase inhibitor 5-azacytidine (Vidaza, Pharmion) elicits complete and partial hematological responses in about 50% of patients with MDS, improves quality of life, and prolongs the time to AML transformation, compared with supportive care. Thalidomide has produced [...]